Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort

Overview of attention for article published in Experimental Hematology & Oncology, October 2019

Altmetric Badge

About this Attention Score

Average Attention Score compared to outputs of the same age
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 3 X users

Citations

dimensions_citation: 17 Dimensions

Readers on

mendeley: 23 Mendeley

Summary X Dimensions citations

So far, Dimensions has found 17 publications that cite this research output.

17

The most recent citing publications are shown below. View all 17 publications that cite this research output on Dimensions.

EGFR degraders in non‐small‐cell lung cancer: Breakthrough and unresolved issue

Article in Chemical Biology & Drug Design (April 2024)

The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies

Article in Critical Reviews in Oncology/Hematology (February 2024)

Accelerated drug resistant variant discovery with an enhanced, scalable mutagenic base editor platform

Preprint in bioRxiv (October 2023)

This page shows the most recent citations of this research output.

Click here to find out how to access more activity.